SARS-CoV-2 was first detected in late December 2019, however, in the few months that followed, the resultant COVID-19 disease has developed into a devastating pandemic around the world [[1]]. This has led to a race to produce a safe and efficacious vaccine in record time.
ReadMore than one-third of the world’s population is exposed to Plasmodium vivax malaria, mainly in Asia1. P. vivax preferentially invades reticulocytes (immature red blood cells)2,3,4. Previous work has identified 11 parasite proteins involved in reticulocyte invasion, including erythrocyte binding protein 2 (ref. 5) and the reticulocyte-binding proteins (PvRBPs)6,7,8,9,10.
ReadObjectives: The emergence of a SARS-CoV-2 variant with a point mutation in the spike (S) protein, D614G, has taken precedence over the original Wuhan isolate by May 2020. With an increased infection and transmission rate, it is imperative to determine whether antibodies induced against the D614 isolate may cross-neutralise against the G614 variant.
Read